Global Partners LP
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Slifka
- Full Time Employees
- 4,700
- Sector
- Industrials
- Industry
- Industrial - Distribution
- Address
- 800 South Street Waltham MA United States of America 02454-9161
- IPO Date
- Oct 4, 2005
- CIK
- 0001323468
- Website
- globalp.com
- Similar Companies
- Business
- Global Partners LP Global Partners LP (NYSE: GLP), a master limited partnership founded in 2005 with roots tracing back to 1933, serves as a leading midstream logistics and marketing company headquartered in Waltham, Massachusetts. The company engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates including diesel and heating oil, residual oil, renewable fuels such as biodiesel and ethanol, crude oil, propane, natural gas, and bunker fuel to wholesalers, retailers, gasoline station operators, sub-jobbers, commercial and industrial end-users, and public sector customers; it operates through three segments—Wholesale, which supplies branded and unbranded gasoline, home heating oil, kerosene, and residual oil via railcars, barges, trucks, and pipelines; Gasoline Distribution and Station Operations (GDSO), which distributes fuels to over 1,700 owned, leased, or supplied retail locations featuring convenience stores, prepared foods, car washes, lottery, and ATM services primarily across Northeast states, the Mid-Atlantic, and Texas; and Commercial, which delivers custom-blended fuels and energy products with a focus on the Northeast U.S. Global maintains dedicated storage at 54 liquid energy terminals connected to rail, pipeline, and marine assets spanning from Maine to Florida and into the U.S. Gulf States, while offering low-carbon solutions like GlobalGLO to support carbon footprint reduction. In recent developments, Global Partners LP completed the acquisition of a 959,730-barrel liquid energy terminal in East Providence, Rhode Island, from ExxonMobil Oil Corporation in November 2024, enhancing gasoline infrastructure, truck rack capacity, and supply optionality for its Northeast retail and marketing operations while adding surplus real estate for future development; the company also issued $450 million in senior unsecured notes due 2033 in June 2025, co-issued with GLP Finance Corp. and guaranteed by subsidiaries, to bolster its capital structure amid ongoing terminal expansions and diversification into renewable fuels.
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Citi lifts Novo Nordisk target on strong GLP-1 pill launch
One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win
3 Refining & Marketing MLPs With Strong Industry Tailwinds
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Study flags need to monitor frailty risks with GLP-1 drugs for older adults
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026
Rejuvenate Muscle Health(TM) Expands its Position in the Emerging GLP-1 Muscle Health Category with U.S. Pharmacy Program and National E-Commerce Expansion
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss